UCB continues to grow
Posted by
25-Oct-2016
UCB’s revenue for the first nine months of 2016 show the company continuing on its growth path, driven by growth of our main products.
Our nine-month interim report, released today, confirms our financial outlook for 2016 trending towards the upper end of the range. Translation: we are continuing to execute well and deliver on our targets.
As we head into the home straight of FY 2016, we expect - trending towards the upper end of the ranges - annual revenue to be approximately € 4.0 - 4.1 billion. Recurring EBITDA should increase to approximately € 970 - 1 010 million. Core earnings per share are expected in the range of € 2.90 - 3.20 based on an expected average of 188 million shares outstanding.
This is driven by growth in sales of our main products. Net sales of our top four products combined reached net sales of € 2.3 billion (+12%).
The interim report is also an opportunity to provide an update on our product portfolio and news from our research and development pipeline.
Our epilepsy product portfolio has grown in the EU, North America and Japan. Meanwhile, US authorities have accepted UCB's filing for a proposed new indication for our top immunology product to treat juvenile idiopathic arthritis.
We are also giving patients new ways to deliver our medicines. The European Medicines Agency has given a positive opinion on the use of the AutoClicks® prefilled pen for the administration of UCB’s treatment for autoimmune disorders. Our researchers are also studying the impact of our products on patients with psoriasis.
There was more good news from a phase 3 research program on the treatment of osteoporosis, including the filing in the U.S. The first positive results from these studies are inspiring UCB and our partner to continue to make preparations to bring the medicine to people with osteoporosis.
For more information on our research pipeline and more, click here to read the report or contact me directly: antje.witte@ucb.com.
Our nine-month interim report, released today, confirms our financial outlook for 2016 trending towards the upper end of the range. Translation: we are continuing to execute well and deliver on our targets.
As we head into the home straight of FY 2016, we expect - trending towards the upper end of the ranges - annual revenue to be approximately € 4.0 - 4.1 billion. Recurring EBITDA should increase to approximately € 970 - 1 010 million. Core earnings per share are expected in the range of € 2.90 - 3.20 based on an expected average of 188 million shares outstanding.
This is driven by growth in sales of our main products. Net sales of our top four products combined reached net sales of € 2.3 billion (+12%).
The interim report is also an opportunity to provide an update on our product portfolio and news from our research and development pipeline.
Our epilepsy product portfolio has grown in the EU, North America and Japan. Meanwhile, US authorities have accepted UCB's filing for a proposed new indication for our top immunology product to treat juvenile idiopathic arthritis.
We are also giving patients new ways to deliver our medicines. The European Medicines Agency has given a positive opinion on the use of the AutoClicks® prefilled pen for the administration of UCB’s treatment for autoimmune disorders. Our researchers are also studying the impact of our products on patients with psoriasis.
There was more good news from a phase 3 research program on the treatment of osteoporosis, including the filing in the U.S. The first positive results from these studies are inspiring UCB and our partner to continue to make preparations to bring the medicine to people with osteoporosis.
For more information on our research pipeline and more, click here to read the report or contact me directly: antje.witte@ucb.com.
Leave a Comment